Clinical trials: Schizophreniform Disorder
Schizophrenia, Psychotic Disorder NOS
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
The primary objective of this study is to determine if NAC, added to existing antipsychotic treatment, is superior to placebo for cortical erosion in patients with early stage psychosis.
- Conditions
- Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
- Trial name
- Breier-Stanley (NCT01339858)
- Testing
- N-Acetyl Cysteine, sugar pill
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indiana University
Schizophrenia, Schizophreniform Disorder
DECIFER: Depression and Citalopram In First Episode Recovery
This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients.
- Trial name
- DECIFER (NCT01041274)
- Testing
- Citalopram, Psychoeducation, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Schizophreniform Disorder, Schizoaffective Disorder
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder.
- Conditions
- Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major
- Trial name
- NCT00421954
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizophreniform Disorder
Integrated Care in Psychotic Disorders With Severe Mental Illness
The study examine the effectiveness of an integrated care program including therapeutic assertive community treatment (ACT) for people with psychotic disorders fulfilling severe and persistent mental illness (SPMI, ACCESS-II…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder
- Trial name
- ACCESS-II (NCT01888627)
- Testing
- Integrated care
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizophreniform Disorders
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
This study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness
- Conditions
- Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder
- Trial name
- NCT03187769
- Testing
- ALKS 3831, Olanzapine
- Where
- 57 sites in United States, Austria and 10 more
- Volunteers
- 426 people
- Sponsor
- Alkermes, Inc.
First Episode Psychosis, Schizophrenia, Childhood
Early Psychosis Intervention - Spreading Evidence-based Treatment
Implementation of 'NAVIGATE' in Ontario aims to help youth and emerging adults suffering from a first episode of psychosis. Although Ontario already has early psychosis intervention programs, the team's recent work has identified…
- Conditions
- First Episode Psychosis, Schizophrenia, Childhood, Psychosis, Schizophrenia
- Trial name
- EPI-SET (NCT03919760)
- Testing
- NAVIGATE, Treatment as Usual
- Where
- 6 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia Disorder, Schizophreniform Disorder
MicroRNAs as Biomarkers in First Episode Schizophrenia
This study investigates whether tiny molecules called microRNAs (miRNAs), found in special brain-derived "packages" (neural-derived extracellular vesicles, or NDEs) that travel from the brain into the blood, can serve as helpful…
- Conditions
- Schizophrenia Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
- Trial name
- MIRFEST (NCT07703670)
- Testing
- Plasma NDE miRNA Sequencing, Whole Genome Sequencing
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis
This study will assess the effectiveness of an experimental treatment intervention for adolescents and adults who have experienced their first episode of psychosis during the past two years.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT01216891
- Testing
- Multi-element, team-oriented treatment
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Schizophreniform Disorders
Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy
To test the feasibility of a clinical trial implementing I-CAT, a novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g.
- Trial name
- I-CAT (NCT03067311)
- Testing
- I-CAT, Treatment as Usual
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Psychosis
Minnesota Community-Based Cognitive Training in Early Psychosis
The purpose of this study is to determine whether cognitive training exercises can improve cognitive functioning in young patients with recent-onset psychosis who are being treated in community mental health settings using the…
- Conditions
- Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- Mini-COTES (NCT03079024)
- Testing
- Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Minnesota
Schizophrenia, Schizoaffective Disorder
Horyzons: Implementation in Clinical Practice
A clinical trial investigating the feasibility and acceptability of implementing a moderated online social media platform with therapeutic content, Horyzons, as a part of care received at first-episode psychosis (FEP) clinics…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
- Trial name
- NCT04673851
- Testing
- Horyzons USA
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of North Carolina, Chapel Hill
Psychosis, Psychosis Nos/Other
EPI-MINN: Targeting Cognition and Motivation - National
The purpose of this study is to perform a practice-based research project designed to assess whether cognition and motivated behavior in early psychosis can be addressed as key treatment goals within real-world settings by using…
- Conditions
- Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder
- Trial name
- NCT05877716
- Testing
- Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Minnesota
Schizophrenia, Schizophreniform
Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia
The purpose of this study is to test the efficacy of transcranial direct current stimulation (tDCS) for the treatment of auditory hallucinations in patients currently on risperidone treatment who are experiencing recent onset…
- Conditions
- Schizophrenia, Schizophreniform, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
- Trial name
- NCT02661347
- Testing
- Risperidone, tDCS
- Where
- United States
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Brain Circuits in Schizophrenia and Smoking
The principle aim of the project is to identify the key brain circuits associated with smoking and especially smoking in high risk population.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT01425684
- Where
- United States
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.
- Trial name
- TEOSS (NCT00053703)
- Testing
- Risperidone, Olanzapine (enrollment closed in this treatment), Molindone
- Where
- 4 sites in United States
- Volunteers
- 116 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizo Affective Disorder
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05756855
- Testing
- adapted behavioral intervention
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Schizophrenia
A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis
The purpose of the study is to assess the effectiveness and safety of long-acting injectable risperidone in the treatment of patients in the early stage of psychosis
- Trial name
- NCT00216580
- Testing
- Risperidone, long-acting injectable
- Volunteers
- 50 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium